UroGen Pharma Ltd.
Price Action
Technical Summary
STAGE 2 UPTRENDUroGen Pharma Ltd. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 49% provides fundamental context to the price action. However, price is extended 23% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $30.45 | +13.43% | ABOVE |
| 50 SMA | $28.17 | +22.60% | ABOVE |
| 100 SMA | $23.94 | +44.25% | ABOVE |
| 150 SMA | $23.55 | +46.66% | ABOVE |
| 200 SMA | $22.48 | +53.67% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is URGN in an uptrend right now?
URGN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, URGN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is URGN overbought or oversold?
URGN's RSI (14) is 70. The stock is in neutral territory, neither overbought nor oversold.
Is URGN outperforming the market?
URGN has a Relative Strength (RS) Rating of 93 out of 99. Yes, URGN is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is URGN in its 52-week range?
URGN is trading at $34.54, which is 96% of its 52-week high ($36.08) and 93% above its 52-week low ($12.73).
How volatile is URGN?
URGN has a Beta of 1.24 and 52-week volatility of 67%. It's more volatile than the S&P 500 - expect bigger swings.